妇科恶性肿瘤患者在辅助治疗期间常出现贫血，其中以缺铁性贫血最为常见。贫血降低患者对治疗的耐受性，引起治疗延迟、减量甚至中断，导致患者对化疗药物耐药、对放疗敏感性降低。纠正贫血可以改善患者预后，规范地进行贫血管理至关重要。常用的治疗方式包括铁剂、红细胞生成刺激剂（ESAs）和输血，其中第三代静脉铁剂因其具有快速纠正铁缺乏、减少输血风险、单次输注更加便利等优势，成为妇科恶性肿瘤患者辅助治疗期间贫血管理的新选择。

Anemia frequently occurs in gynecologic malignancy patients undergoing adjuvant therapy，with iron-deficiency anemia （IDA） being the most prevalent. Anemia reduces patients' tolerance to treatment，leading to therapy delays，dose reductions，or even discontinuation. This may result in chemotherapy resistance and decreased radiotherapy sensitivity. Correcting anemia can improve prognosis，so standardized anemia management is essential. Common therapeutic approaches include iron supplementation，erythropoiesis-stimulating agents （ESAs），and blood transfusions. Among these，third-generation intravenous iron preparations have emerged as a new option in the anemia management in adjuvant therapy for patients with gynecological malignancies due to their rapid iron repletion，reduced transfusion risks，and the convenience of single-dose administration.